The American Association for Cancer Research (AACR) is the world's oldest and largest professional association related to cancer research. The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine.
At AACR in April 2021, Imugene presented pre-clinical studies of the eradication of distant peritoneal tumors by the intratumoral delivery of CHECKvacc (CF33-hNIS-PDL1) and positive HER-VAXX Phase 2 results in gastric cancer. In the week of these presentations the SP commenced its climb from 14 cents to 62 cents in November 2021.
At AACR in April 2023, Imugene presented positive imaging results and tracking of CHECKvacc (CF33-hNIS-PDL1) replication in patients with TNBC. This was the first known report of successful hNIS-based imaging to track oncolytic poxvirus replication in humans.
In November 2023, Imugene announced positive early signals in the MAST trial of the parental oncolytic virus VAXINIA (CF33-hNIS) and evidence of pseudo-progression in the complete response of a mid-dose patient in biliary tract cancer now in remission for over 430 days.
On the 5th April 2024, AACR will convene its annual general meeting San Diego California
https://www.aacr.org/meeting/aacr-annual-meeting-2024/And while there is no confirmation at this stage that Imugene will present, abstracts will be available online on the 5th March 2024.
Following the recent January 2024 announcement that patients have been dosed at 3x10^8 in the 5th cohort of monotherapy for both IT and IV on the 16th and 18th January respectively we know that their first 42 day scan results will be taken by the end of this month.
I am looking forward to these results being presented as well as further exanples of pseudo-progression at AACR 2024. I believe this could well provide the much awaited impetus for another momentous climb in the SP.
This company is world class. I continue to be amazed with the safety profile and ground breaking results of Imugene's IP.
GLTA - Go Team Imugene
(20min delay)